A programmed death receptor-1 inhibitor——Tislelizumab

doi:10.3969/j.issn.1672-3384.2022.01.004

PDF(434 KB)

Clinical Medication Journal ›› 2022, Vol. 20 ›› Issue (1) : 37-42. DOI: 10.3969/j.issn.1672-3384.2022.01.004

Comment of new drugs

A programmed death receptor-1 inhibitor——Tislelizumab

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2022, 20(1): 37-42 https://doi.org/10.3969/j.issn.1672-3384.2022.01.004

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(434 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2021-10-30	2022-01-28
Issue Date
2022-01-28

Please choose a citation manager

Content to export